Sands Capital recently shared its Q4 2024 investor letter about the Select Growth Fund. This fund focuses on U.S. companies shaping the economy positively. The fund achieved an 8.8% return in the fourth quarter, outpacing its benchmark.
- Fund returned 8.8% in Q4 2024.
- Benchmark return was 7.1%.
- Over one year, fund returned 24.3% vs. 33.4% for the benchmark.
- Edwards Lifesciences' stock fell 23.15% in the past year.
- March 31, 2025 share price was $72.48.
| Time Period | Edwards Lifesciences Return |
|---|---|
| 1 Month | 1.54% |
| Last 52 Weeks | -23.15% |
